Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
atopic dermatitis
biomarkers
dupilumab
p-EASI
pediatric
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
07
10
2022
received:
19
08
2022
accepted:
02
11
2022
entrez:
24
12
2022
pubmed:
25
12
2022
medline:
28
12
2022
Statut:
ppublish
Résumé
Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are available. The aim of this study is to evaluate the effect of 28 weeks dupilumab treatment on effectiveness, safety, and serum biomarkers in pediatric patients with moderate-to-severe AD in daily practice. Patients visited the outpatient clinic at baseline, 4, 16, and 28 weeks of treatment. Disease severity was assessed by the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), Numeric Rating Scale (NRS)-pruritus and -pain, and the Patient-Oriented Eczema Measure (POEM). Side effects were evaluated. Nineteen severity-associated serum biomarkers were measured. Predicted-EASI (p-EASI) was calculated. Sixty-one patients were included. Respectively 75.4%, 49.2%, and 24.6% reached EASI-50, EASI-75, and EASI-90 and 36.1% achieved an IGA-score (almost) clear. Improvement of ≥4 points on POEM, NRS-pruritus, and NRS-pain was reached by 84.7%, 45.3%, and 77.4%, respectively. Most reported side effects were conjunctivitis (n = 10) and headache (n = 4). Biomarkers TARC, PARC, periostin, sIL-2Ra, and eotaxin-3 significantly decreased during treatment. The p-EASI showed a significant correlation with disease severity. Dupilumab treatment significantly improved disease severity and disease-associated symptoms and decreased severity-associated serum biomarkers in pediatric AD patients in daily practice.
Sections du résumé
BACKGROUND
Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are available. The aim of this study is to evaluate the effect of 28 weeks dupilumab treatment on effectiveness, safety, and serum biomarkers in pediatric patients with moderate-to-severe AD in daily practice.
METHODS
Patients visited the outpatient clinic at baseline, 4, 16, and 28 weeks of treatment. Disease severity was assessed by the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), Numeric Rating Scale (NRS)-pruritus and -pain, and the Patient-Oriented Eczema Measure (POEM). Side effects were evaluated. Nineteen severity-associated serum biomarkers were measured. Predicted-EASI (p-EASI) was calculated.
RESULTS
Sixty-one patients were included. Respectively 75.4%, 49.2%, and 24.6% reached EASI-50, EASI-75, and EASI-90 and 36.1% achieved an IGA-score (almost) clear. Improvement of ≥4 points on POEM, NRS-pruritus, and NRS-pain was reached by 84.7%, 45.3%, and 77.4%, respectively. Most reported side effects were conjunctivitis (n = 10) and headache (n = 4). Biomarkers TARC, PARC, periostin, sIL-2Ra, and eotaxin-3 significantly decreased during treatment. The p-EASI showed a significant correlation with disease severity.
CONCLUSION
Dupilumab treatment significantly improved disease severity and disease-associated symptoms and decreased severity-associated serum biomarkers in pediatric AD patients in daily practice.
Identifiants
pubmed: 36564878
doi: 10.1111/pai.13887
pmc: PMC10107870
doi:
Substances chimiques
dupilumab
420K487FSG
Biomarkers
0
Immunoglobulin A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13887Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Acta Derm Venereol. 2021 Feb 17;101(2):adv00402
pubmed: 33491094
Br J Dermatol. 2020 Jan;182(1):85-96
pubmed: 31595499
Allergy. 2020 Dec;75(12):3287-3289
pubmed: 33305359
Cytokine. 2018 Jun;106:114-124
pubmed: 29089178
Curr Opin Allergy Clin Immunol. 2015 Oct;15(5):453-60
pubmed: 26226355
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1292-1299
pubmed: 35412683
Allergol Int. 2019 Apr;68(2):285-286
pubmed: 30711305
Prev Sci. 2007 Sep;8(3):206-13
pubmed: 17549635
Inflammation. 2016 Jun;39(3):1253-67
pubmed: 26861136
J Allergy Clin Immunol. 2017 Dec;140(6):1703-1705
pubmed: 28823810
Allergy. 2019 Mar;74(3):613-617
pubmed: 30368864
J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2423-2429
pubmed: 35854650
Pediatr Allergy Immunol. 2022 Dec;33(12):e13887
pubmed: 36564878
Dermatol Ther. 2021 May;34(3):e14933
pubmed: 33751751
Ann Allergy Asthma Immunol. 2021 Apr;126(4):417-428.e2
pubmed: 33421555
Rev Paul Pediatr. 2017 Jan-Mar;35(1):5-10
pubmed: 28977306
Acta Derm Venereol. 2012 Sep;92(5):502-7
pubmed: 22170091
Arch Dermatol. 2004 Dec;140(12):1513-9
pubmed: 15611432
JAMA Dermatol. 2020 Jan 1;156(1):44-56
pubmed: 31693077
J Allergy Clin Immunol Pract. 2022 Sep;10(9):2378-2385
pubmed: 35753667
Dermatol Ther. 2022 Aug;35(8):e15588
pubmed: 35569129
J Am Acad Dermatol. 2020 Feb;82(2):407-411
pubmed: 31606479
Arch Dermatol Res. 2021 Dec;313(10):855-861
pubmed: 33547939
Exp Dermatol. 2001 Feb;10(1):11-8
pubmed: 11168575
J Am Acad Dermatol. 2020 Nov;83(5):1282-1293
pubmed: 32574587
Br J Dermatol. 2021 May;184(5):857-870
pubmed: 32969489
J Allergy Clin Immunol. 2019 Jan;143(1):155-172
pubmed: 30194992
Allergy. 2020 Jan;75(1):116-126
pubmed: 31593343
Pediatr Dermatol. 2021 Sep;38(5):1178-1184
pubmed: 34515353